BRAF and neoplasm: The deregulation of miR-146b was linked with aggressive behaviour of tumours in clinical PTC specimens positive for BRAF and individuals containing BRAF mutations showed elevated expressions of miR-146b as compared to BRAF wild-type controls (107, 108).